| Identification | Back Directory | [Name]
ENROFLOXAIN HYDROCHLORIDE | [CAS]
93106-59-3 | [Synonyms]
ENROFLOXAIN HYDROCHLORIDE
3-Quinolinecarboxylic acid, 1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-, Monohydrochloride (9CI) | [EINECS(EC#)]
274-614-4 | [Molecular Formula]
C19H23ClFN3O3 | [MOL File]
93106-59-3.mol | [Molecular Weight]
395.856 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
H2O: 2 mg/mL, clear (Warmed) | [form ]
Solid | [color ]
White to off-white | [Water Solubility ]
Water : 7.14 mg/mL (Need ultrasonic) | [InChI]
InChI=1S/C19H22FN3O3.ClH/c1-2-21-5-7-22(8-6-21)17-10-16-13(9-15(17)20)18(24)14(19(25)26)11-23(16)12-3-4-12;/h9-12H,2-8H2,1H3,(H,25,26);1H | [InChIKey]
PZJWYUDBXNNVLZ-UHFFFAOYSA-N | [SMILES]
N1(C2CC2)C2=C(C=C(F)C(N3CCN(CC)CC3)=C2)C(=O)C(C(O)=O)=C1.[H]Cl |
| Hazard Information | Back Directory | [Uses]
Enrofloxacin monohydrochloride (BAY Vp 2674 monohydrochloride) is an effective antibiotic with an MIC90 of 0.312 μg/mL for Mycoplasma bovis. Enrofloxacin monohydrochloride shows inhibitory activity against vaccinia virus (VV). | [in vivo]
Mice (n=80) undergo transient middle cerebral artery occlusion (MCAo) with reperfusion after 60 minutes. After MCAo, animals are randomly assigned to receive either a daily preventive medication (n=26, Enrofloxacin) starting at the day of MCAo or a therapeutic medication (n=25; Enrofloxacin) after diagnosis of lung infection. Standard treatment started immediately after the appearance of clinical signs (general health score>6) usually between day 4 and 6 after stroke. Both, preventive and standard antibiotic treatment using Enrofloxacin improve survival in a similar way compared with placebo treatment[2]. | [IC 50]
Quinolone | [References]
[1] Sulyok KM, et al.Antibiotic susceptibility profiles of Mycoplasma bovis strains isolated from cattle in Hungary, Central Europe. BMC Vet Res. 2014 Oct 25;10:256. DOI:10.1186/s12917-014-0256-x
[2] Hetze S, et al. Superiority of preventive antibiotic treatment compared with standard treatment of poststroke pneumonia in experimental stroke: a bed to bench approach. J Cereb Blood Flow Metab. 2013 Jun;33(6):846-54. DOI:10.1038/jcbfm.2013.6
[3] S Ikeda , et al. Antiviral activity and inhibition of topoisomerase by ofloxacin, a new quinolone derivative. Antiviral Res. 1987 Oct;8(3):103-13. DOI:10.1016/0166-3542(87)90064-7 |
|
| Company Name: |
TargetMol
|
| Tel: |
400-821-0310 15002144251 |
| Website: |
www.targetmol.cn/ |
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|